HomeCompareMARUY vs PFE

MARUY vs PFE: Dividend Comparison 2026

MARUY yields 1.82% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MARUY wins by $42.87M in total portfolio value
10 years
MARUY
MARUY
● Live price
1.82%
Share price
$357.52
Annual div
$6.50
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.92M
Annual income
$38,823,958.22
Full MARUY calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — MARUY vs PFE

📍 MARUY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMARUYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MARUY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MARUY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MARUY
Annual income on $10K today (after 15% tax)
$154.64/yr
After 10yr DRIP, annual income (after tax)
$33,000,364.49/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, MARUY beats the other by $32,977,235.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MARUY + PFE for your $10,000?

MARUY: 50%PFE: 50%
100% PFE50/50100% MARUY
Portfolio after 10yr
$21.49M
Annual income
$19,425,584.38/yr
Blended yield
90.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MARUY
No analyst data
Altman Z
2.5
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MARUY buys
0
PFE buys
0
No recent congressional trades found for MARUY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMARUYPFE
Forward yield1.82%6.20%
Annual dividend / share$6.50$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$42.92M$51.1K
Annual income after 10y$38,823,958.22$27,210.54
Total dividends collected$42.58M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MARUY vs PFE ($10,000, DRIP)

YearMARUY PortfolioMARUY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,064$363.85$9,161$701.38+$1.9KMARUY
2$12,591$752.45$8,610$859.79+$4.0KMARUY
3$15,073$1,600.56$8,366$1,081.25+$6.7KMARUY
4$19,709$3,581.43$8,483$1,405.66+$11.2KMARUY
5$29,842$8,753.48$9,084$1,907.24+$20.8KMARUY
6$56,705$24,773.69$10,418$2,732.78+$46.3KMARUY
7$148,663$87,988.42$13,007$4,193.56+$135.7KMARUY
8$590,243$431,174.03$18,010$7,005.87+$572.2KMARUY
9$3,831,395$3,199,835.16$28,216$12,979.89+$3.80MMARUY
10$42,923,551$38,823,958.22$51,081$27,210.54+$42.87MMARUY

MARUY vs PFE: Complete Analysis 2026

MARUYStock

Marubeni Corporation engages in various business activities worldwide. The company trades in grains, feed ingredients, compound feeds, foods, agricultural and fishery products, and fresh and processed meat; and apparel, footwear, lifestyle, and textile and industrial materials. It also provides agri-inputs, contracting services for fertilizer application and crop protection products, technical services, crop protection product formulations, fertilizers, and oilseeds; ICT and real estate services; petrochemicals and plastics, salts and chlor-alkalis, life science products, electronic materials, and inorganic mineral resources and chemicals; and wood chips, biomass fuels, pulp and waste papers, paper, paperboards, sanitary, and building and construction materials, as well as wood products. In addition, the company explores for, develops, and produces oil and gas; trades in, distributes, and markets petroleum and LPG; develops uranium, nuclear fuel cycle, iron ore, coal, and copper mines, as well as related equipment sales and services; smelts and refines aluminum and magnesium; trades in iron ore, coking coal, non-ferrous metals, ingots and related products, and steel products; and leases temporary steel construction materials. Further, it offers engineering, procurement, and construction, as well as operation and maintenance services for railway systems, water, industrial plants, and waste-to-energy power plants; energy and transportation infrastructure, and water business; and manages infrastructure funds, as well as engages in the power generation, renewable energy, power service and retail, natural gas, hydrogen, ammonia, municipal solid waste, and thermal energy storage businesses. Additionally, it owns, purchases, operates, leases, sells, and charters aerospace and ship products; and sells, trades in, leases, finances, and services construction and industrial machinery, and mobility products. The company was founded in 1858 and is headquartered in Tokyo, Japan.

Full MARUY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MARUY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MARUY vs SCHDMARUY vs JEPIMARUY vs OMARUY vs KOMARUY vs MAINMARUY vs JNJMARUY vs MRKMARUY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.